Article: Biologicals in severe chronic rhinosinusitis with nasal polyps: translation to clinical practice while waiting for head-to-head studies.
2023 Volume 61, Issue 3, Page(s) 283–286
Abstract: Chronic rhinosinusitis with nasal polyps (CRSwNP) affects 1.0-2.6% of the population (1) and results in relevant direct and indirect costs. Recently, several randomized controlled trials (RCTs) with Type 2-targeting biologicals (anti-IL4Rα, anti-IL5R, ... ...
Abstract | Chronic rhinosinusitis with nasal polyps (CRSwNP) affects 1.0-2.6% of the population (1) and results in relevant direct and indirect costs. Recently, several randomized controlled trials (RCTs) with Type 2-targeting biologicals (anti-IL4Rα, anti-IL5R, anti-IL5 and anti-IgE) opened a new treatment field for patients refractory to first-line treatments (2,3). |
---|---|
MeSH term(s) | Humans ; Rhinitis/drug therapy ; Biological Products/therapeutic use ; Nasal Polyps/drug therapy ; Sinusitis/drug therapy ; Chronic Disease |
Chemical Substances | Biological Products |
Language | English |
Publishing date | 2023-03-28 |
Publishing country | Netherlands |
Document type | Journal Article |
ZDB-ID | 80336-4 |
ISSN | 0300-0729 |
ISSN | 0300-0729 |
DOI | 10.4193/Rhin22.436 |
Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
Zs.A 1080: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.